medwireNews: The second-generation anti-CD40L monoclonal antibody frexalimab shows sustained benefit over 48 weeks in patients with relapsing multiple sclerosis (MS), show findings presented at the 10th Congress of the European Academy of Neurology.
11-07-2024 | Multiple Sclerosis | News